International Circulation: It has been reported that compared with diuretics and β-blocker， CCB and ACEI/ARB do a better job of reducing central blood pressure. Does that mean CCB and ACEI/ARB should be given priority in antihypertensive treatment?
Takazawa：Yes， I think so.
Vasodilator agents reduce mainly late systolic pressure which increases with increasing arterial stiffness and causes cardiac afterload. On the other hand， diuretics and β-blocker mainly reduces the ejection pressure. So， for the purpose of reduction in cardiovascular accidents in hypertensive patients， I do believe that vasodilator agents must be used as first choice of treatment.
《国际循环》：有报道显示，与利尿剂和β阻滞剂相比，CCB和ACEI/ARB能够更有效地降低中心动脉压。这是否意味着降压治疗应优先选择CCB和ACEI/ARB？
Takazawa教授：是的。扩血管药物主要降低晚期SBP，晚期SBP升高会增加动脉僵硬度和心脏后负荷。另一方面，利尿剂和β阻滞剂主要降低心室射血时的血压，因此为了达成减少高血压患者心血管事件的目的，我的确认为应当将扩血管药物作为一线治疗。